探讨齐拉西酮与奥氮平治疗首发精神分裂症的临床效果

Discussion on clinical effect of ziprasidone and olanzapine in the treatment of first-episode schizophrenia

目的探讨齐拉西酮与奥氮平治疗首发精神分裂症患者的临床效果和安全性。方法 108例首发精神分裂症患者,随机分为对照组和研究组,各54例。对照组患者采用奥氮平治疗,研究组采用齐拉西酮治疗。比较两组疗效和不良反应情况。结果研究组痊愈19例,显效21例,有效11例,无效3例,总有效率为94.44%,对照组痊愈12例,显效15,有效17例,无效10例,总有效率为81.48%;研究组总有效率高于对照组,差异有统计学意义(P<0.05)。研究组不良反应发生率为3.70%(2/54),低于对照组的14.81%(8/54),差异有统计学意义(P<0.05)。结论齐拉西酮对难治性精神分裂症患者的治疗效果比较突出,不良反应较少,针对性较强,方便可靠,临床中可以进行推广使用。

Objective To discuss the clinical effect and safety of ziprasidone and olanzapine in the treatment of first-episode schizophrenia patients. Methods A total of 108 first-episode schizophrenia patients were randomly divided into control group and research group, with 54 cases in each group. The control group was treated with olanzapine, and the research group was treated with ziprasidone. Comparison were made on efficacy and adverse reactions between two groups. Results The research group had 19 cured cases, 24 excellent cases, 11 effective cases and 3 ineffective cases, with total effective rate as 94.44%, while the control group had 12 cured cases, 15 excellent cases, 17 effective cases and 10 ineffective cases, with total effective rate as 81.48%. The research group had higher total effective rate than the control group, and the difference was statistically significant（P〈0.05）. The research group had lower incidence of adverse reactions as 3.70%（2/54） than 14.81%（8/54） in the control group, and the difference was statistically significant（P〈0.05）. Conclusion Ziprasidone shows prominent effect in the treatment of refractory schizophrenia patients with less adverse reactions. It is targeted, convenient and reliable, and can be popularized and used in clinic.